Therefore, the higher sensitivity to Olaparib or AZD2461 observed in RH30 cells compared to RD cells might partially be explained by the more pronounced down-regulation of PTEN levels in the alveolar compared to the embryonal cell line (our preliminary data not shown), this underlying the usefulness of PARPi treatment in tumours with deregulated HR-linked proteins, such as PTEN, independently to the BRCA1/2 status alone. Here, PTEN is linked to neoplasm.